Asuragen, Illumina Partner
News Sep 10, 2015
Asuragen will leverage its Quantidex™ NGS product platform for development of customized companion diagnostics for its biotech and pharma partners on the Illumina MiSeqDx™ instrument. Asuragen’s recently launched Quantidex™ Pan Cancer Kit* demonstrates its optimized NGS system that unifies pre-analytical DNA QC, sample quantification, multiplex PCR enrichment, dual-index barcoding, and library purification and quantification, using reagents provided in a single kit. In addition, it integrates Asuragen’s analytics and reporting suite, the Quantidex™ Reporter, providing a straight forward sample-to-answer solution for Asuragen NGS panels.
“We are uniquely positioned to be a nimble and high quality companion diagnostic partner to biotech and pharma”, said Matt McManus, President and CEO of Asuragen. “Sequencing-based companion diagnostic projects benefit from our established Quantidex™ NGS product platform, which allows for rapid and efficient development of a unique DNA and/or RNA panel of interest. The Quantidex™ NGS system is built under design control and manufactured in our cGMP facility, providing a high quality basis for regulated diagnostic product development.”
Researchers have used a method to develop a new blood marker capable of detecting whether or not a person has Alzheimer’s disease. If the method is approved for clinical use, the researchers hope eventually to see it used as a diagnostic tool in primary healthcare. This autumn, they will start a trial in primary healthcare to test the technique.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE